文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SARS-CoV-2 病毒载量与疾病严重程度和死亡率的增加有关。

SARS-CoV-2 viral load is associated with increased disease severity and mortality.

机构信息

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.

出版信息

Nat Commun. 2020 Oct 30;11(1):5493. doi: 10.1038/s41467-020-19057-5.


DOI:10.1038/s41467-020-19057-5
PMID:33127906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7603483/
Abstract

The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.

摘要

SARS-CoV-2 病毒载量与 2019 年冠状病毒病(COVID-19)疾病进展风险之间的关系在很大程度上尚未明确。在这里,我们从患有各种严重程度 COVID-19 的参与者中定量检测了 SARS-CoV-2 病毒载量,包括需要住院治疗的患者、轻症门诊患者和已康复的感染者。我们在 27%的住院患者和 13%的 COVID-19 门诊患者中检测到了 SARS-CoV-2 血浆 RNA。在因 COVID-19 住院的患者中,我们报告说,可检测到的 SARS-CoV-2 血浆病毒载量越高,与更严重的呼吸道疾病严重程度、更低的绝对淋巴细胞计数以及更高的炎症标志物(包括 C 反应蛋白和 IL-6)相关。SARS-CoV-2 病毒载量,特别是血浆病毒血症,与死亡率增加相关。我们的数据表明,SARS-CoV-2 病毒载量可能有助于 COVID-19 患者的风险分层,因此其在疾病发病机制中的作用应进一步探讨。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/240acc3d1d90/41467_2020_19057_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/45a502da36d7/41467_2020_19057_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/b507239db93b/41467_2020_19057_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/e493c2a49171/41467_2020_19057_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/240acc3d1d90/41467_2020_19057_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/45a502da36d7/41467_2020_19057_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/b507239db93b/41467_2020_19057_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/e493c2a49171/41467_2020_19057_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec0/7603483/240acc3d1d90/41467_2020_19057_Fig4_HTML.jpg

相似文献

[1]
SARS-CoV-2 viral load is associated with increased disease severity and mortality.

Nat Commun. 2020-10-30

[2]
RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients.

Viruses. 2020-9-18

[3]
SARS-CoV-2 RNAemia in a Healthy Blood Donor 40 Days After Respiratory Illness Resolution.

Ann Intern Med. 2020-11-17

[4]
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.

EBioMedicine. 2020-9-16

[5]
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.

Lancet Infect Dis. 2020-3-23

[6]
Serial serum SARS-CoV-2 RNA results in two COVID-19 cases with severe respiratory failure.

J Infect Chemother. 2020-11

[7]
Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.

Med Microbiol Immunol. 2020-8-28

[8]
SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.

J Clin Virol. 2020-9-1

[9]
Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques.

Cell Res. 2020-7-7

[10]
Interleukin-6 as a potential biomarker of COVID-19 progression.

Med Mal Infect. 2020-6

引用本文的文献

[1]
Specific Matrix on the Basis of Angiotensin-Converting Enzyme 2: Development and Functional Analysis.

Bull Exp Biol Med. 2025-8-28

[2]
Humoral and Memory B Cell Responses Following SARS-CoV-2 Infection and mRNA Vaccination.

Vaccines (Basel). 2025-7-28

[3]
Association Between ABO Blood Groups and SARS-CoV-2 RNAemia, Spike Protein Mutations, and Thrombotic Events in COVID-19 Patients.

Pathogens. 2025-7-31

[4]
Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection.

Pathog Immun. 2025-7-9

[5]
Recent advances in CRISPR-based single-nucleotide fidelity diagnostics.

Commun Med (Lond). 2025-7-1

[6]
Droplet Digital PCR or Real-Time PCR as a Method for Quantifying SARS-CoV-2 RNA in Plasma-Is There a Difference?

Viruses. 2025-5-28

[7]
The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation.

J Biomed Sci. 2025-6-26

[8]
Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients.

PLoS Comput Biol. 2025-6-9

[9]
Characteristics of SARS-CoV-2 variants and potential co-infected pathogens in hospitalized patients based on metagenomic next-generation sequencing.

Sci Rep. 2025-5-29

[10]
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.

JCI Insight. 2025-5-22

本文引用的文献

[1]
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

N Engl J Med. 2020-9-3

[2]
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

N Engl J Med. 2020-5-21

[3]
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Lancet. 2020-4-29

[4]
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Cell. 2020-5-15

[5]
Multiorgan and Renal Tropism of SARS-CoV-2.

N Engl J Med. 2020-8-6

[6]
Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.

Histopathology. 2020-8

[7]
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.

N Engl J Med. 2020-5-14

[8]
Endothelial cell infection and endotheliitis in COVID-19.

Lancet. 2020-5-2

[9]
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.

Cell Host Microbe. 2020-4-21

[10]
COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure.

Thromb Haemost. 2020-4-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索